Medtronic’s SynchroMed II Infusion Pain Treatment Proves Cost-Effective In Study
Executive Summary
A new cost-effectiveness study shows cancer patients using targeted drug delivery with Medtronic’s SynchroMed II infusion system and conventional medical management incur lower overall health care costs than patients using conventional medical management alone.